{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:11:20Z","timestamp":1794028280370,"version":"4.8.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANTHEA"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We aimed to (1) analyze the applicability of the updated Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations in real-world clinical practice, (2) identify barriers to their implementation, and (3) propose practical measures to overcome these obstacles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This qualitative study was based on a survey, a literature review, and expert opinions. Nine inflammatory bowel disease (IBD) experts identified 7 areas likely to be controversial or potential implementation barriers in daily clinical practice: endoscopy, histology, ultrasound, quality of life, biomarkers, symptom control, and patient-reported outcomes (PROs). Based on this, a survey was carried out among educational course participants. The experts discussed the literature review and survey results and proposed several statements and practical actions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 55 gastroenterologists answered the survey. The reported difficulty level in reaching STRIDE-II treatment goals in clinical practice was high. Only 22% of participants performed clinical remission assessments using clinical indexes and PROs. Seventy percent of responders did not use fecal calprotectin cutoffs and considered changes from the previous levels instead. Mucosal healing as a long-term therapeutic goal was considered necessary to be individualized in specific patient subgroups (eg, elderly\/fragile patients, multiple treatment failures, and last-line therapies). Other barriers, like the lack of access to imaging techniques or insufficient knowledge and skills among healthcare professionals, were detected. The experts suggested adding less stringent treatment goals and measurements, patient stratification, local adaptations, educational activities, and research.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>STRIDE-II recommendations face various implementation barriers needing careful evaluation in order to enhance their adoption in clinical practice, and ultimately improve outcomes in IBD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae055","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:22:14Z","timestamp":1728559334000},"source":"Crossref","is-referenced-by-count":6,"title":["Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-1594","authenticated-orcid":false,"given":"Elena","family":"Ricart","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic Barcelona, IDIBAPS, CIBEREHD , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Bastida","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, La Fe University and Polytechnic Hospital , Valencia 46026 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carpio","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigaci\u00f3n Sanitaria Galicia Sur (IISGS) , Pontevedra 36071 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-4524","authenticated-orcid":false,"given":"Daniel","family":"Ceballos","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Doctor Negrin , Las Palmas de Gran Canaria 35010 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ginard","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Son Espases , Palma de Mallorca 07120 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Mar\u00edn-Jimen\u00e9z","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Hospital Universitario Gregorio Mara\u00f1\u00f3n-Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mench\u00e9n","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Hospital Universitario Gregorio Mara\u00f1\u00f3n-Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario de Salamanca , Salamanca 37007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitario 12 de Octubre , Madrid 28041 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"1","key":"2024102310251804600_CIT0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alabat","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2024102310251804600_CIT0002","doi-asserted-by":"crossref","first-page":"1334308","DOI":"10.3389\/fpsyg.2024.1334308","article-title":"Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients","volume":"15","author":"Bernabeu","year":"2024","journal-title":"Front Psychol."},{"issue":"3","key":"2024102310251804600_CIT0003","doi-asserted-by":"crossref","first-page":"otad027","DOI":"10.1093\/crocol\/otad027","article-title":"Utility of intestinal ultrasound in clinical decision-making for inflammatory bowel disease","volume":"5","author":"Saleh","year":"2023","journal-title":"Crohns Colitis 360."},{"issue":"11","key":"2024102310251804600_CIT0004","first-page":"e48338","article-title":"Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of Inflammatory Bowel Disease (IBD): a systematic review","volume":"15","author":"Ashraf","year":"2023","journal-title":"Cureus."},{"issue":"11","key":"2024102310251804600_CIT0005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2024102310251804600_CIT0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"8","key":"2024102310251804600_CIT0007","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S2468-1253(21)00096-0","article-title":"Transmural healing as a therapeutic goal in Crohn\u2019s disease: a systematic review","volume":"6","author":"Geyl","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"9","key":"2024102310251804600_CIT0008","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024102310251804600_CIT0009","doi-asserted-by":"crossref","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"2","key":"2024102310251804600_CIT0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2024102310251804600_CIT0011","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2024102310251804600_CIT0012","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17474124.2023.2296564","article-title":"To STRIDE or not to STRIDE: a critique of \u201ctreat to target\u201d in Crohn\u2019s disease","volume":"17","author":"Herrlinger","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"5","key":"2024102310251804600_CIT0013","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.17622","article-title":"Review article: translating STRIDE-II into clinical reality\u2014opportunities and challenges","volume":"58","author":"Dignass","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2024102310251804600_CIT0014","volume-title":"CEBM Levels of Evidence 2011","author":"CEBM., Medicine. CfEB","year":"2011"},{"issue":"1","key":"2024102310251804600_CIT0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2024102310251804600_CIT0016","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000487589","article-title":"Multiparametric evaluation predicts different mid-term outcomes in Crohn\u2019s disease","volume":"36","author":"Laterza","year":"2018","journal-title":"Dig Dis."},{"issue":"1","key":"2024102310251804600_CIT0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.MIB.0000195391.49762.89","article-title":"Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health","volume":"12","author":"Farrokhyar","year":"2006","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2024102310251804600_CIT0018","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1440-1746.2011.06624.x","article-title":"Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status","volume":"26","author":"Bryant","year":"2011","journal-title":"J Gastroenterol Hepatol."},{"key":"2024102310251804600_CIT0019","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.pecinn.2022.100034","article-title":"Treatment goals in IBD: a perspective from patients and their partners","volume":"1","author":"Peek-Kuijt","year":"2022","journal-title":"PEC Innov."},{"issue":"3","key":"2024102310251804600_CIT0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","article-title":"Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis","volume":"27","author":"Rokkas","year":"2018","journal-title":"J Gastrointestin Liver Dis."},{"issue":"11","key":"2024102310251804600_CIT0021","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.dld.2014.07.013","article-title":"Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor \u03b1 agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year","volume":"46","author":"Guidi","year":"2014","journal-title":"Dig Liver Dis."},{"issue":"12","key":"2024102310251804600_CIT0022","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"19","key":"2024102310251804600_CIT0023","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3748\/wjg.v25.i19.2354","article-title":"Combined evaluation of biomarkers as predictor of maintained remission in Crohn\u2019s disease","volume":"25","author":"Sollelis","year":"2019","journal-title":"World J Gastroenterol."},{"issue":"4","key":"2024102310251804600_CIT0024","doi-asserted-by":"crossref","first-page":"748","DOI":"10.14309\/ajg.0000000000002122","article-title":"Prevalence and correlations of gastrointestinal symptoms with endoscopic and histologic mucosal healing in Crohn\u2019s disease","volume":"118","author":"Tse","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2024102310251804600_CIT0025","first-page":"304","article-title":"Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s disease","volume":"26","author":"Lewis","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024102310251804600_CIT0026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cgh.2014.07.055","article-title":"A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2024102310251804600_CIT0027","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","article-title":"Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2024102310251804600_CIT0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474124.2020.1759416","article-title":"Mucosal healing in Crohn\u2019s disease: new insights","volume":"14","author":"Cucchiara","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"1","key":"2024102310251804600_CIT0029","first-page":"Cd011450","article-title":"Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis","volume":"1","author":"Mohammed Vashist","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"2024102310251804600_CIT0030","first-page":"Cd010642","article-title":"Endoscopic scoring indices for evaluation of disease activity in Crohn\u2019s disease","volume":"2016","author":"Khanna","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"2024102310251804600_CIT0031","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"11","key":"2024102310251804600_CIT0032","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/MIB.0000000000000155","article-title":"Assessment of histologic disease activity in Crohn\u2019s disease: a systematic review","volume":"20","author":"Mojtahed","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2024102310251804600_CIT0033","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/MIB.0000000000001143","article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn\u2019s disease","volume":"23","author":"Fernandes","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2024102310251804600_CIT0034","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ibd\/izy074","article-title":"Predictors of durability of radiological response in patients with small bowel Crohn\u2019s disease","volume":"24","author":"Deepak","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024102310251804600_CIT0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gastrohep.2017.10.003","article-title":"Recommendations of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn\u2019s Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in inflammatory bowel disease patients","volume":"41","author":"Barreiro-de Acosta","year":"2018","journal-title":"Gastroenterol Hepatol."},{"issue":"12","key":"2024102310251804600_CIT0036","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/MEG.0000000000001885","article-title":"Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations","volume":"32","author":"Casellas","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"10","key":"2024102310251804600_CIT0037","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1046\/j.1525-1497.2003.10205.x","article-title":"Randomized controlled trial of education and feedback for implementation of guidelines for acute low back pain","volume":"18","author":"Schectman","year":"2003","journal-title":"J Gen Intern Med."},{"issue":"3","key":"2024102310251804600_CIT0038","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10620-023-08220-9","article-title":"IBD-PODCAST Spain: a close look at current daily clinical practice in IBD management","volume":"69","author":"Vega","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2024102310251804600_CIT0039","doi-asserted-by":"crossref","first-page":"17562848231184986","DOI":"10.1177\/17562848231184986","article-title":"Challenges in the diagnosis and management of IBD: a sub-Saharan African perspective","volume":"16","author":"Watermeyer","year":"2023","journal-title":"Therap Adv Gastroenterol."},{"issue":"2","key":"2024102310251804600_CIT0040","doi-asserted-by":"crossref","first-page":"otae027","DOI":"10.1093\/crocol\/otae027","article-title":"Strategies for enhancing inflammatory bowel disease care in Pakistan: bridging gaps and building capacities","volume":"6","author":"Devi","year":"2024","journal-title":"Crohns Colitis 360."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae055\/59704345\/otae055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae055\/59981041\/otae055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae055\/59981041\/otae055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:25:49Z","timestamp":1729679149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae055\/7816903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae055","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"otae055"}}